Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Immunotherapy for advanced gastric cancer: Experience from Uzbekistan.

Kamila Izrailbekova, Sergey Kamishov, Askar Adilkhodjaev et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23352

e23352 Background: Gastric cancer is a major cause of cancer-related mortality worldwide and remains highly prevalent in C...

Efficacy and safety of adjuvant immune checkpoint inhibitors in resected renal cell carcinoma: Systematic review and meta-analysis of phase III trials.

Fadi Abualhommos, Leena Alhusari, Rahaf Fetyani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16514

e16514 Background: Phase III trials of adjuvant immune checkpoint inhibitors (ICIs) in resected renal cell carcinoma (RCC)...

Spectrum of autosomal recessive pediatric cancer predisposition syndromes in a population with high consanguinity.

Mayada Abu Shanap, Hikmat Abdel-Razeq, Esmé Waanders et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22637

e22637 Background: Most studies of pediatric cancer predisposition syndromes (CPS) are derived from Western populations, r...

Association of estrogen receptor status with survival outcomes in neuroendocrine carcinoma of the breast: A SEER Research Plus analysis (2010–2021).

Maryam Ali, Syed Musharraf Shah Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12759

e12759 Background: Neuroendocrine carcinoma of the breast (NECB) is a rare histologic sub-type with heterogeneous clinical...

Early inpatient chemotherapy in central nervous system (CNS) tumors: Predictors, treatment patterns, and in-hospital outcomes.

Fiqe Khan, Davin Turku, Abdullah Ahmad et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14035

e14035 Background: Timely inpatient chemotherapy may alter the trajectory of acute CNS tumor hospitalizations by controlli...

RADIANCE predictive score: A new model of radiological markers for prediction of antiangiogenics efficacy in pretreated metastatic colorectal carcinoma (mCRC)—RADIANCE trial.

Antonella Nicastro, Maria Chiara Brunese, Arianna Cesario et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15553

e15553 Background: Antiangiogenic agents are widely used in mCRC. The ABACO trial recently showed that high angiogenesis g...

Surrogate end points for overall survival: A meta-analysis exploring adequacy of progression-free survival and objective response in randomized NSCLC trials.

Nehemias Guevara, Wint Yan Aung, Hector J. Garcia Pleitez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20702

e20702 Background: Surrogate endpoints such as progression-free survival (PFS) and objective response rate (ORR) are widel...

Incorporating CA19-9 testing in a prospective study of pancreatic cancer surveillance (PCS) among high-risk individuals (HRIs).

Asaf Maoz, Leah Biller, Alyson Caruso et al. Jun 01, 2026 pp. 10527-10527 10.1200/jco.2026.44.16_suppl.10527

10527 Background: For individuals at an increased risk of pancreatic cancer (PC), imaging-based PCS is recommended. Howeve...

Epidemiological trends and burden of liver cancer mortality due to hepatitis B in Sub-Saharan Africa: A retrospective analysis from 1990 to 2023 with advanced machine learning forecasting to 2050.

Umme Kulsum, Ibrahim Khalil, Nabila Nur et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16233

e16233 Background: Liver cancer due to hepatitis B virus (HBV) remains a major cause of cancer mortality in sub-Saharan Af...

Comprehensive genomic profiling of matched ctDNA and tissue from patients with four common cancers enrolled to the NCI-MATCH trial.

Rini Pauly, Biswajit Das, Chris Alan Karlovich et al. Jun 01, 2026 pp. 3045-3045 10.1200/jco.2026.44.16_suppl.3045

3045 Background: In the NCI-MATCH trial (NCT02465060), tumor tissue from 5,954 patients with advanced cancers underwent ne...

First-line fovinaciclib versus placebo combined with aromatase inhibitor for advanced breast cancer: A randomized, double-blind phase 3 study.

Peng Yuan, Binghe Xu, Yunjiang Liu et al. Jun 01, 2026 pp. 1090-1090 10.1200/jco.2026.44.16_suppl.1090

1090 Background: Endocrine therapy combined with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor is the standard fir...

Antitumor activity of amivantamab by consensus molecular subtypes in <i>RAS</i> / <i>BRAF</i> wild-type metastatic colorectal cancer: Secondary analyses from the phase 1b/2 OrigAMI-1 study.

Marcia Roxana Cruz-Correa, Sae-Won Han, Rozita Abdul Malik et al. Jun 01, 2026 pp. 3548-3548 10.1200/jco.2026.44.16_suppl.3548

3548 Background: Colorectal tumors are classified by mutational subtypes and sidedness, which inform treatment and outcome...

Temporal patterns of irAE onset by treatment regimen and organ system in a pan-cancer ICI-treated cohort.

Min Jung Koh, Mackayla Uy, Julia Contini et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23398

e23398 Background: Immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) can manifest at heteroge...

The association between social capital and cancer screening rates in the United States.

Tarfa Verinumbe, Ariana N. Neely, Chidiebube Ugwu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22550

e22550 Background: Cancer screening remains a cornerstone of cancer prevention, yet substantial geographic variation persi...

Minimally invasive vs open pancreaticoduodenectomy for periampullary tumors: A systematic review and updated meta-analysis.

Oscar Toro Ruilowa, Arbab Khalid, Khadija Mohib et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16474

e16474 Background: Laparoscopic pancreaticoduodenectomy (LPD) is increasingly being performed for periampullary tumors. Ho...

A phase I study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of KH617 for patients with advanced solid tumors (including diffuse gliomas of adulthood).

Wenbin Li, Zhuang Kang, Shenglan Li et al. Jun 01, 2026 pp. 2046-2046 10.1200/jco.2026.44.16_suppl.2046

2046 Background: Outcomes in patients (pts) with recurrent glioblastoma (rGBM) are poor, with historical median overall su...

Clinical features and outcomes of EBER-negative nasopharyngeal carcinoma: A large cohort study across China.

Yue Xia, Na Guo, Cong Zhang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18144

e18144 Background: The current TNM staging system and treatment guidelines are primarily based on EBER-positive nasopharyn...

ALFA score as a predictor of long-term benefit with frontline brigatinib in <i>ALK</i> + advanced NSCLC: A ctDNA-based composite biomarker from ALTA-1L.

Laura Mezquita, Miquel Ferriol-Galmes, Victor Albarran-Artahona et al. Jun 01, 2026 pp. 8646-8646 10.1200/jco.2026.44.16_suppl.8646

8646 Background: Optimal sequencing of ALK-TKI in 1st-line ALK+ NSCLC remains cont...

Open, laparoscopic, versus robotic surgery for Siewert type II/III adenocarcinoma of esophagogastric junction: A systematic review and Bayesian network meta-analysis.

Bara M. Hammadeh, Faizan Sheraz, Yousef Alghzawi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16093

e16093 Background: The optimal surgical approach for Siewert type II/III adenocarcinoma of the esophagogastric junction (A...

GZMK+ T cells in glioblastoma and an activated, non-exhausted phenotype.

Agnese Losurdo, Alberto Susana, Angelo Dipasquale et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14071

e14071 Background: Glioblastoma (GBM) bears a survival estimate below 10% at 5 years, despite surgery and standard chemora...

Pre-transplant MRD negativity and TP53 mutation status determine survival after CAR-T therapy bridged to allo-HSCT for refractory/relapse B-ALL.

Zhihui Li, Qinlong Zheng, Keyan Yang et al. Jun 01, 2026 pp. 6556-6556 10.1200/jco.2026.44.16_suppl.6556

6556 Background: The feasibility and outcomes of bridging relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia...

Patient experience and quality of life in a decentralized cancer care model for advanced prostate cancer.

Roxana Stefania Dronca, Trevanne Rose Matthews Hew, Adam McLain Kase et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13611

e13611 Background: Decentralized cancer care models may reduce treatment burden for patients with advanced prostate cancer...

A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck.

Jacob Stephen Thomas, Justine Yang Bruce, Jochen H. Lorch et al. Jun 01, 2026 pp. 6006-6006 10.1200/jco.2026.44.16_suppl.6006

6006 Background: Single agent pembrolizumab in relapsed/metastatic head and neck squamous cell carcinoma (R/M HNSCC) has l...

A clinicopathological and molecular profiling study of <i>EGFR</i> mutations in a cohort of 215 lung cancer patients from Eastern India.

Amitabh Ray, Chandan Mandal, Chandrani Mallik et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20708

e20708 Background: Epidermal Growth Factor Receptor (EGFR) mutations are a critical biomarker in non-small cell lung cance...

CXCR4/CXCL12 antagonism to disrupt microenvironment-mediated resistance for autologous transplant conditioning in multiple myeloma: A systematic review and mechanistic synthesis.

Jason A. Starr, Suzanne Rose, Christopher J. Del Prete et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19523

e19523 Background: Despite advances in therapy, multiple myeloma remains incurable, with relapse driven by residual diseas...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page